Does Pyott Recognize Valeant / Ackman Potential Value Creation For Allergan Shareholders?

As the court battle between Allergan, Inc. (NYSE:AGN), Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and activist hedge fund manager Bill Ackman of Pershing Square Capital plays itself out in court, the fate of research and development at what was considered one of the better run corporations in the US stands in the balance, according to sealed documents obtained by ValueWalk (see the documents at the end of this article).

The trial could be the make-or-break point for Allergan, which is expected by some hedge fund insiders to lose a shareholder proxy vote this December 18, particularly if Pershing Square votes their own shares, an issue in dispute.

Allergan challenging Valeant and Bill Ackman to fend off acquisiton

To fend off the...